Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending September 20, 2020 High-risk prostate cancer: Outcomes of neurovascular bundle preservation, Prostate cancer: Outcomes of surveillance, prostatectomy, and radiotherapy, mCRPC: Rucaparib demonstrates activity in phase 2, Prostate cancer: Delaying radiotherapy after ADT not linked to poor overall survival, mCRPC: Docetaxel-carboplatin improves outcomes after second-generation hormone therapy, More must reads Must reads for theWeek ending September 6, 2020 New blood-based test for prostate cancer, mCRPC: Survival advantage of enzalutamide maintained in the long term, Perirectal hydrogel spacer may lower prostate radiotherapy-induced rectal toxicities, Radiotherapy after radical prostatectomy worsens sexual, urinary function, Routine use of neoadjuvant chemohormonal therapy not supported in localized high-risk prostate cancer, More must readsMust reads for theWeek ending August 23, 2020 Fracture risk in prostate cancer survivors, Radical prostatectomy vs deferred treatment for localized prostate cancer, mHSPC: Antibiotic prophylaxis for febrile neutropenia, Localized prostate cancer: HIFU may be an effective option, Prostate cancer: Ablation yields poor survival vs radiotherapy, More must readsMust reads for theWeek ending August 9, 2020 Localized prostate cancer: Effect of frailty and comorbidity on surgical contraindication, Prostate cancer: Intermittent adjuvant ADT schedule fails to demonstrate noninferiority, Do PPIs influence prostate cancer outcomes?, PSA decay constant is predictive of treatment outcome after salvage radiotherapy, Prostate cancer: Postdiagnosis weight gain linked to greater mortality risk, More must readsMust reads for theWeek ending July 26, 2020 MRI-targeted biopsy yields a superior prostate cancer detection rate, Prostate cancer: Nerve-sparing surgery is a predictor of positive margins, Prostate cancer: 5α-Reductase inhibitors may delay progression, T2DM tied to lower prostate cancer risk, Localized prostate cancer: Testosterone therapy is safe in appropriate patients after definitive treatment, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 last »